The founder had two term sheets. Both were from credible investors. One was from a firm she had specifically targeted at the start of the process; the other arrived from a fund that had followed on from her seed. The valuations were within 15% of each other. Both investors had told her they had strong conviction.
She took eleven days to decide. During that time, she had several follow-up calls with each investor, continued to receive inbound expressions of interest from two other funds, and spent considerable time negotiating a higher valuation on the less preferred term sheet to use as leverage against the preferred one. By day nine, the preferred investor had stopped responding within the same day. On day eleven, when she finally called to accept, he told her the partnership had grown more cautious. He was still willing to proceed, but the round was now structured with a lower initial tranche. The effective dilution was worse than either original offer.
She had managed a competitive process for eleven days and ended up with a weaker outcome than either term sheet would have delivered on day one. What she experienced is not unusual. It is the predictable result of treating a competitive process as a negotiation to be maximised rather than a window to be closed at the right moment.
A competitive Series A is not an achievement. It is a management challenge. Most founders who receive competing term sheets are underprepared for the specific decisions it requires.
The Four Decisions That Determine Whether a Competitive Process Creates or Destroys Value
1. The timing problem: signalling competition without manufacturing urgency
The first decision in any competitive fundraise is when and how to signal that competition exists. Most guidance on this question says: signal early, be transparent, use the competition to accelerate decisions. This is correct in principle and frequently executed in ways that sophisticated investors immediately discount.
Manufactured urgency is recognisable. When a founder who has been in conversation with an investor for six weeks suddenly mentions a term sheet expiry date from a fund that has had one meeting with the company, experienced investors do not feel urgency. They feel sceptical. The information has the opposite effect from what was intended.
Genuine urgency is different. It comes from a specific and credible fact: another investor of similar or better quality has indicated they are moving toward a decision on a specific timeline. When that is true, communicating it early in the conversation, not as leverage but as information, creates a legitimate reason for the investor to accelerate their own process. The distinction is between telling an investor “you need to move quickly because I have another offer” and telling an investor “I want to give you enough time to reach conviction: another fund has indicated they’re getting close to a decision in the next two weeks.”
The second version is factual, not threatening, and gives the investor agency to respond. It also happens to be useful information about the state of the market, which is part of what investors are always trying to understand.
The most effective timing for signalling competition is the moment it becomes genuine, specifically when a second investor’s process has reached a stage that could plausibly result in a term sheet before the preferred investor is ready. Earlier than that produces scepticism. Later than that produces less time to act.
2. Exclusivity mechanics: when to grant it, for how long, and what to ask for in return
Exclusivity is the moment a competitive process ends. Once signed, the no-shop provision in a term sheet, standard across virtually all Series A documentation, prohibits the founder from negotiating with other investors for the duration of the exclusivity period. According to Sifted’s UK term sheet data drawn from Mountside Ventures research, 35% of investors in the UK required a four-week exclusivity period (the most common term), while 26% required none at all. Standard exclusivity is 30 days; anything significantly beyond 60 days warrants examination.
Exclusivity should not be granted until four conditions are met. First, the founder has a clear preference between the investors available. Second, the selected investor has demonstrated the specific type of post-investment engagement the company needs, not in general terms but based on reference conversations with portfolio founders. Third, the key economic and governance terms are agreed in substance, not left for negotiation after exclusivity is signed. Fourth, the founder has no remaining high-conviction investor relationships that have not yet had the opportunity to reach their own view.
The last condition is the most commonly violated. Founders sign exclusivity while several investors are still in mid-process, not because the preferred deal is done but because one investor offered a term sheet first and the founder accepted the social pressure to commit. This is a significant strategic error. Exclusivity terminates leverage; it should be granted only when the leverage has already been used.
What to ask for in return for granting exclusivity: a specific closing timeline with a stated consequence for material delay (typically the ability to re-engage other investors if the exclusivity period expires without a signed investment agreement), and if the exclusivity period is longer than 30 days, a cost-coverage provision for legal fees incurred if the investor withdraws.
3. Investor selection criteria when multiple term sheets exist
When multiple term sheets arrive, the default founder instinct is to compare valuations. This is understandable and mostly wrong. Valuation at Series A is a bounded variable: it affects the current round’s dilution, but its importance relative to other terms is consistently overstated in founder decision-making.
The dimensions that most meaningfully affect founder outcomes over the five to eight years following a Series A close are not the ones founders typically negotiate hardest in a competitive process.
According to Cooley LLP’s Q2 2025 venture data, 98% of Series A rounds use a 1x non-participating liquidation preference, and protective provisions appear in over 90% of deals. The headline economics are largely standardised. What varies significantly, and what founders should weight in investor selection, is the following.
Board seat composition: who sits on the board has more influence on company outcomes than any single term in the document. The relevant question is not whether the investor takes a board seat but how they behave on boards, specifically in the moments when the company is struggling and the interests of the investor and the founder are not perfectly aligned. This question should be answered through off-list reference calls with founders who worked with this investor through a difficult period.
Pro-rata rights and follow-on capacity: an investor with the fund size and the stated intention to follow on in future rounds is a materially different partner from one who will be diluted away before Series B. At a competitive Series A, super pro-rata rights should be examined carefully: they can crowd out strategic investors in future rounds and create allocation pressure at exactly the moments when the founder has the most to gain from a competitive Series B process.
Reference quality: the most consistently valuable thing a founder can do in a competitive multi-term-sheet situation is speak to three or four founders who have worked with each investor in a difficult operational period, not as a reference call the investor arranged, but as an independent conversation. The information this produces reliably shifts the investor selection decision in ways that valuation comparison does not.
4. The five terms that most affect founder outcomes versus the five that consume most negotiation energy
| Founders Typically Negotiate Hardest | Why This Gets Attention | What Actually Affects Outcomes | Why This Gets Less Attention |
| Pre-money valuation | Most visible number; directly legible as equity retained | Board composition and investor behaviour under adversity | Not visible in the document; requires qualitative research |
| Option pool size | Directly affects effective valuation (larger pool reduces it) | Pro-rata and super pro-rata rights | Effects materialise over multiple rounds, not at close |
| Liquidation preference multiple | Feels significant; 1x vs 2x is an obvious comparison | Protective provisions scope | Technical language; effects hard to model before seeing one in practice |
| Anti-dilution mechanism | Broad-based weighted average vs full ratchet is a real difference | Information rights and reporting requirements | Operational burden only felt post-close |
| Vesting acceleration on change of control | Relevant only at exit; psychologically salient | Drag-along rights structure | Only materialises at exit; easy to overlook during an active fundraise |
Option pool size is the one exception to the pattern: it directly affects effective pre-money valuation and is worth negotiating carefully because the effect is immediate. The others on the founder-focus list are worth getting right but are less likely to determine outcomes than the right column.
When to Stop Running the Process and Close
The decision framework for closing is simpler than most founders make it. Close when three conditions are simultaneously true: you have reached conviction that the preferred investor is the right partner for this company at this stage; the economic and governance terms on the table are within an acceptable range; and the cost of continuing the process in diluted investor attention and founder time exceeds the expected value of any further improvement.
The last condition is the one most commonly misjudged. Founders in competitive processes often continue running the process after the first two conditions are already met, in pursuit of marginal valuation improvements that are unlikely to materialise and that, if pursued past the point where investors feel genuinely committed, extract a price in relationship quality that shows up in board dynamics for years.
The standard exclusivity period of 30 days closes quickly. The diligence and documentation process then runs four to eight weeks on top of that. The practical answer is: when the investor you would genuinely want to work with for the next five years has put a term sheet on the table at terms that are professionally defensible, the window to accept it is short. Sophisticated investors know when a founder is stalling to manufacture better terms. The goodwill consumed by that process is worth more than the incremental equity you are unlikely to recover.
Close the best available deal when it is genuinely good. Do not optimise it past that point.
Disclaimer: this article is analytical commentary and does not constitute legal or financial advice. All term sheet negotiations should involve qualified legal counsel with specific venture experience.